|
Welcome
|
|
12 February 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | news |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
|
| [ ...Back to search results ] | [ Print-friendly version ] |
| Adolescent type 1 diabetes cardio-renal intervention trial |
| Source of record | UK Trials |
| ISRCTN | ISRCTN91419926 |
| Date ISRCTN assigned | 03/10/2007 |
| Local reference number(s) | RP06 |
| Public title | Adolescent type 1 diabetes cardio-renal intervention trial |
| Scientific title | |
| Acronym | Adolescent Diabetes Intervention Trial (AdDIT) |
| Disease/condition/study domain | Type 1 diabetes |
| Study hypothesis | To determine whether intervention with Angiotensin Converting Enzyme Inhibitors (ACEI), statins, or a combination of both, when compared with placebo, will: 1. Reduce albumin excretion as assessed by six monthly measurement of Albumin/Creatinine Ratio (ACR) in three early morning urines 2. Reduce the incidence of Microalbuminuria (MA) (ACR log mean greater than 3.5 mg/mmol (males) or greater than 4 mg/mmol [females] in two out of three urines) at the end of the study period 3. Reduce the incidence of MA during the six month run out period following the completion of intervention phase |
| Design/methodology | Randomised, controlled, double blind, clinical trial |
| Research ethics review | Ethics approval submitted in August 2007. |
| Countries of trial | United Kingdom, Australia, Canada |
| Participants - inclusion criteria | 1. Type 1 diabetes diagnosed for greater than one year 2. Aged 11 to 15 years 3. High risk for the development of diabetic nephropathy and Cardiovascular Disease (CVD) as predicted by albumin excretion in the upper tertile after appropriate adjustment for age, sex, age at diagnosis and duration of disease |
| Participants - exclusion criteria | 1. Non-type 1 diabetes, i.e., type 2 diabetes, insulin dependent diabetes related to monogenic disease, secondary diabetes 2. ACR based on six early morning urines deemed to be at low risk for subsequent development of CVD or diabetic nephropathy 3. Pregnancy, or unwillingness to comply with contraceptive advice and regular pregnancy testing throughout the trial 4. Severe hyperlipidaemia and family history data to support diagnosis of familial hypercholesterolaemia 5. Established hypertension unrelated to diabetic nephropathy 6. Prior exposure to the investigational products, statins and ACEI |
| Patient information material | |
| Anticipated start date | 01/01/2008 |
| Anticipated end date | 31/12/2012 |
| Status of trial | Ongoing |
| Target number of participants | 500 |
| Interventions | Four arm randomisation: 1. Quinapril, 5 - 10 mg daily and placebo 2. Atorvostatin, 10 mg daily and placebo 3. Quinapril and atorvostatin 4. Placebo The duration of study will be three to four years, that is until subjects reach the age of 14 to 18 years and they will also be studied for an additional six months during the run out period. |
| Primary outcome measure(s) | The primary endpoint is defined as the area under the curve over time of log albumin-creatinine ratio per year, with standardisation for gender, age and duration of disease. |
| Secondary outcome measure(s) | 1. Changes in carotid intimal media thickness, between baseline and the end of intervention period 2. Changes in arterial Blood Pressure (BP), lipids and other lipoproteins, CVD risk markers (high-sensitive C-Reactive Protein [hsCRP] and Asymmetric Dimethylarginine [ADMA]), assessed every six months during the intervention period 3. Changes in measures of Glomerular Filtration Rate (GFR) (plasma Symmetrical Dimethylarginine [SDMA], creatinine and cystatin C) assessed every six months during the intervention period 4. Changes in quality of life and health economics |
| Sources of funding | 1. Diabetes UK (UK) (ref: RD06/0003341) 2. Juvenile Diabetes Research Foundation (UK) (ref: 8-2007-902) 3. British Heart Foundation (UK) (ref: SP/07/002/23394) |
| Sponsor name | University of Cambridge and Cambridge University Hospitals NHS Foundation Trust (UK) |
| Sponsor details | Research Service Division 16 Mill Lane Cambridge United Kingdom CB2 1SB |
| Sponsor email | helen.atkinson@rsd.cam.ac.uk |
| Sponsor website | http://www.cam.ac.uk/ |
| Contact name | Prof David Dunger |
| Contact details | University Department of Paediatrics Box 116, Addenbrooke's Hospital Cambridge United Kingdom CB2 0QQ |
| Contact email | dbd25@cam.ac.uk |
| More information | For more up-to-date information please go to the ISRCTN link below. |
| Link to record in ISRCTN Register | ISRCTN91419926 |
| Date last extracted from ISRCTN register | 17/04/2008 |
|
|
|
|
|
| © 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement | |
|
|
|
|